LobbyingCrinetics Pharmaceuticals lobbying by quarter
Crinetics Pharmaceuticals's latest lobbying report covers Q2 2026, at $60K. The four quarters Q4 2025–Q3 2026 total $180K. Its first report covers Q1 2023; the issues it reports most are Health Issues and Medicare/Medicaid.
Crinetics Pharmaceuticals
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $180K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q1 2023
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2023 | $20K | 1 |
| Q2 2023 | $60K | 1 |
| Q3 2023 | $60K | 1 |
| Q4 2023 | $60K | 1 |
| Q1 2024 | $80K | 2 |
| Q2 2024 | $120K | 2 |
| Q3 2024 | $120K | 2 |
| Q4 2024 | $60K | 1 |
| Q1 2025 | $60K | 1 |
| Q2 2025 | $60K | 1 |
| Q3 2025 | $60K | 1 |
| Q4 2025 | $60K | 1 |
| Q1 2026 | $60K | 1 |
| Q2 2026 | $60K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$380K · 7 reports
- Health issues$280K · 10 reports
- Medicare and Medicaid$280K · 10 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)15 reports
- HOUSE OF REPRESENTATIVES10 reports
- SENATE10 reports
- Food & Drug Administration (FDA)7 reports
Firms it paid
| Firm | ||
|---|---|---|
| Tarplin, Downs & Young | $560K | 10 quarters |
| Rubicon Advisors | $380K | 7 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| CHARLOTTE SPEARS IVANCIC | Leg. Counsel, Sen. Jim DeMint; Health Counsel, Maj. Leader Bill Frist; Counsel and Budget Analyst, House Budget Cmte.; Asst. to the Speaker for Policy, Speaker John Boehner | Q2 2026 |
| PETER FISE | Health Counsel for Sen. Cmte on Finance, Health Counsel for Sen. Jeanne Shaheen, Staff Assistant for House Cmte on Oversight & Government Reform | Q2 2026 |
| LAURA FRIEDEL | Leg. Asst., Sen. Zell Miller, Leg. Dir., Sen. Richard Shelby, Clerk, Staff Dir., Sen. Appropriations Committee | Q3 2025 |
| KIMBERLY LYNN BRANDT | Sr. Counsel and Dir. External Affairs - HHS OIG; Prin. Dep. Administrator for Policy and Operations, and Dir. of Medicare Program Integrity - CMS; Chief Oversight and General Counsel, Sen. Cmte. on Finance | Q4 2024 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Tarplin, Downs & Young | $60K |
| 04/20for Q1 | Tarplin, Downs & Young | $60K |
| 01/20for Q4 2025 | Tarplin, Downs & Young | $60K |
| 25/10/20for Q3 2025 | Tarplin, Downs & Young | $60K |
| 25/07/21for Q2 2025 | Tarplin, Downs & Young | $60K |
| 25/04/21for Q1 2025 | Tarplin, Downs & Young | $60K |
| 25/01/21for Q4 2024 | Tarplin, Downs & Young | $60K |
| 24/10/29for Q1 2024 | Rubicon Advisors | $60K |
| 24/10/22for Q3 2024 | Rubicon Advisors | $60K |
| 24/10/18for Q3 2024 | Tarplin, Downs & Young | $60K |
| 24/07/22for Q2 2024 | Tarplin, Downs & Young | $60K |
| 24/07/21for Q2 2024 | Rubicon Advisors | $60K |
| 24/07/21for Q1 2024 | Rubicon Advisors | $60K |
| 24/07/21for Q4 2023 | Rubicon Advisors | $60K |
| 24/07/21for Q3 2023 | Rubicon Advisors | $60K |
| 24/07/21for Q2 2023 | Rubicon Advisors | $60K |
| 24/07/21for Q2 2023 | Rubicon Advisors | $60K |
| 24/07/21for Q1 2023 | Rubicon Advisors | $20K |
| 24/07/17for Q1 2023 | Rubicon Advisors | Under $5,000 |
| 24/04/22for Q1 2024 | Tarplin, Downs & Young | $20K |